Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Braess

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Leukemia|July 13, 2007
AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemiaF Schneider, S K Bohlander, S Schneider, et al.
Annals of Hematology|May 6, 2004
Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cellsM Bornhäuser, T Illmer, P Le Coutre, et al.
Bone Marrow Transplantation|March 2, 2011
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot studyC Schmid, M Schleuning, J Tischer, et al.
Leukemia|December 19, 2017
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemiaM Rothenberg-Thurley, S Amler, D Goerlich, et al.
Leukemia|June 11, 2014
Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapseT Köhnke, D Sauter, K Ringel, et al.
Leukemia|October 24, 2013
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCGM Fiegl, M Unterhalt, W Kern, et al.
Leukemia|June 1, 2011
An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemiaT Herold, V Jurinovic, K H Metzeler, et al.
Leukemia|September 11, 2009
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCGE Lengfelder, C Haferlach, S Saussele, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancerA Kron, C Alidousty, M Scheffler, et al.
Leukemia|March 12, 2016
Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemiaT Büchner, U O Krug, R Peter Gale, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Leukemia|July 13, 2007
AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemiaF Schneider, S K Bohlander, S Schneider, et al.
Annals of Hematology|May 6, 2004
Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cellsM Bornhäuser, T Illmer, P Le Coutre, et al.
Bone Marrow Transplantation|March 2, 2011
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot studyC Schmid, M Schleuning, J Tischer, et al.
Leukemia|December 19, 2017
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemiaM Rothenberg-Thurley, S Amler, D Goerlich, et al.
Leukemia|June 11, 2014
Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapseT Köhnke, D Sauter, K Ringel, et al.
Leukemia|October 24, 2013
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCGM Fiegl, M Unterhalt, W Kern, et al.
Leukemia|June 1, 2011
An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemiaT Herold, V Jurinovic, K H Metzeler, et al.
Leukemia|September 11, 2009
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCGE Lengfelder, C Haferlach, S Saussele, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancerA Kron, C Alidousty, M Scheffler, et al.
Leukemia|March 12, 2016
Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemiaT Büchner, U O Krug, R Peter Gale, et al.
Pageof 6